A Prospective External Control Arm Study in Colorectal Cancer (COLOSSAL)
NPM-009/COLOSSAL: A Prospective, Always-On Study to Generate Standardized External Control Arms Across Metastatic and MRD-Positive Early-Stage Colorectal Cancer
The goal of this observational, external control arm study is to make clinical trials faster, speed up developments of new therapies, and make trials more accessible to patients being treated at community oncology clinics.
調査の概要
状態
条件
詳細な説明
The purpose of this research is to better understand what treatments are given to patients with colorectal cancer, how the disease responds to treatments, and the generate reliable data that can be used as a comparison for new drugs in development.
研究の種類
入学 (推定)
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with early stage or metastatic colorectal cancer
説明
Global Inclusion Criteria:
- 18 years at the time of initial colorectal cancer diagnosis
- Able to understand and provide informed consent
- Pathologically confirmed colorectal cancer per College of American Pathologists (CAP) guidelines
- Evidence of biomarker testing on tissue and/or blood
Early Stage CRC Inclusion Criteria
- Stage II-III disease per AJCC
- Positive ctDNA MRD results for specimen collected 4-8 weeks after curative intent surgery and before any adjuvant therapy
- Planning to start adjuvant therapy, or started it within the past 6 weeks prior to enrollment
- ECOG performance status of 0 or 1, documented on or within 21 days before the start of adjuvant therapy
- CT of the chest, abdomen, and pelvis (CT CAP) with contrast performed after surgery and up to 6 weeks prior to the start of adjuvant therapy
Metastatic CRC Inclusion Criteria
- Stage IV disease per AJCC or metastatic recurrence
- Planning to start adjuvant therapy, or started within the past 6 weeks prior to enrollment
- ECOG performance status of 0 or 1 documented on or within 21 days before the start of the new line of therapy
- CT of the chest, abdomen, and pelvis (CT-CAP) with contrast performed after surgery and up to 6 weeks prior to the start of a new line of therapy
Exclusion Criteria:
- Current enrollment in an interventional clinical trial
- Active therapy for a second, unrelated malignancy (excluding hormonal adjuvant therapy for breast cancer)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
|---|
|
Early Stage MRD positive
|
|
Metastatic disease
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS)
時間枠:5 years
|
Time from index date to the first evidence of progression assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on protocol imaging, or death, whichever occurs first. bicrPFS (months)=[(earliest date of BICR progression, death, or censoring-index date) +1] / 30.4375 |
5 years
|
|
Overall Response Rate (ORR)
時間枠:5 years
|
Proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) during a given line of therapy, from index until progression or the start of the next line, whichever occurs first, assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on-protocol imaging. Ranked CR ≥ PR ≥ stable disease (SD) ≥ progressive disease (PD) ≥ not evaluable (NE). CR and PR are confirmed by a subsequent assessment at least 28 days later. When the minimum interval is not met, BOR is determined by subsequent assessments. Participants lost to follow-up after an SD assessment that does not meet the minimum interval have a BOR of NE. bicrORR (%) = (number of participants with BOR of CR or PR from index until earliest date of BICR progression or next line start ÷ number of participants in the response population) × 100 |
5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to Next Treatment (TTNT)
時間枠:5 years
|
Time from index to the start of the next line of therapy or death, whichever occurs first. Participants who do not initiate a next line of therapy are censored at earliest of loss to followup and data cutoff. TTNT (months) = [(earliest date of next line start, death, or censoring - index date) + 1] ÷ 30.4375. |
5 years
|
|
Overall Survival (OS)
時間枠:5 years
|
Time from index to death from any cause. A missing date of death indicates the participant is alive at data cutoff, and the participant is censored at data cutoff. OS (months) = [(earliest date of death or censoring - index date) + 1] ÷ 30.4375 |
5 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。